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Marc Beyer,3,4 Patrick Gu¨nther,1 Jonas Schulte-Schrepping,1 Lea Seep,1 Kathrin Klee,1 Thomas Ulas,1
Torsten Haferlach,5 Sach Mukherjee,2,7,* and Joachim L. Schultze1,4,7,8,*
SUMMARY
Acute myeloid leukemia (AML) is a severe, mostly fatal hematopoietic malignancy. We were inter-
ested in whether transcriptomic-based machine learning could predict AML status without requiring
expert input. Using 12,029 samples from 105 different studies, we present a large-scale study of ma-
chine learning-based prediction of AML inwhichwe address key questions relating to the combination
of machine learning and transcriptomics and their practical use. We find data-driven, high-dimensional
approaches—in which multivariate signatures are learned directly from genome-wide data with no
prior knowledge—to be accurate and robust. Importantly, these approaches are highly scalable
with low marginal cost, essentially matching human expert annotation in a near-automated workflow.
Our results support the notion that transcriptomics combined with machine learning could be used as
part of an integrated -omics approach wherein risk prediction, differential diagnosis, and subclassifi-
cation of AML are achieved by genomics while diagnosis could be assisted by transcriptomic-based
machine learning.
INTRODUCTION
Recommendations for the diagnosis and management of malignant diseases are organized by interna-
tional expert panels. For example, the first edition of the European LeukemiaNet (ELN) recommendations
for the diagnosis and management of acute myeloid leukemia (AML) in adults was published in 2010 (Do¨h-
ner et al., 2010) and recently revised in 2017 (Do¨hner et al., 2017). Based on recent DNA sequencing results,
such as those derived from The Cancer Genome Atlas, AML can be subdivided into multiple subclasses
(Arber et al., 2016; Ding et al., 2012; Ley et al., 2008, 2010; Loriaux et al., 2008; Papaemmanuil et al.,
2016; The Cancer Genome Atlas Research Network (TCGA) et al., 2013; Welch et al., 2012; Yan et al.,
2011). Leukemias are characterized by strong transcriptomic signals, as seen in a pioneering study almost
two decades ago by Golub et al. (Golub et al., 1999) and a rich body of subsequent work (Debernardi et al.,
2003; Kohlmann et al., 2003; Ross et al., 2004; Schoch et al., 2002; Virtaneva et al., 2001). These findings led
to the suggestion that gene expression profiling (GEP) could be utilized to define leukemia subtypes and
derive useful predictive gene signatures (Andersson et al., 2007; Bullinger et al., 2004). Nevertheless, ac-
cording to the ELN recommendations primary diagnosis still relies on classical approaches including
assessment of morphology, immunophenotyping, cytochemistry, and cytogenetics (Do¨hner et al., 2017).
Although undoubtedly effective in detecting disease, these existing diagnostic approaches rely on large
investments in human expertise (training and employment of specialists) and physical infrastructure, whose
costs scale with the number of samples. This has implications for accessibility (e.g., in rural areas or outside
developed regions) and on cost and logistical grounds alone limits the scope to consider alternatives to the
overall decision pipeline. In contrast to classical diagnostic pipelines that are centered on interpretation of
results by human experts, artificial intelligence- (AI) and machine learning- (ML) based approaches have
the potential for low marginal cost (i.e., cost per additional sample once the system is trained) (Esteva
et al., 2017), and this key aspect of AI and ML is widely appreciated in the economics literature (see,
e.g., Brynjolfsson and McAfee, 2014).
The potential of GEP for leukemia diagnosis has been recognized. A decade after the pioneering work
of Golub et al., the International Microarray Innovations in Leukemia Study Group proposed GEP by micro-
array analysis to be a robust technology for the diagnosis of hematologic malignancies with high accuracy
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(Haferlach et al., 2010). The utility of GEP by RNA sequencing (RNA-seq) has been also demonstrated for
other tumor entities, for example, breast cancer (Ciriello et al., 2015; Kristensen et al., 2012; Parker et al.,
2009), bladder cancer, or lung cancer (Hoadley et al., 2014; Robertson et al., 2017). Furthermore, in AML
research large RNA-seq datasets have been described in the meantime (Garzon et al., 2014; Lavallee
et al., 2016; Lavalle´e et al., 2015; Macrae et al., 2013; Pabst et al., 2016).
In parallel, a series of advances in ML, AI, and computational statistics have transformed our understanding
of prediction using high-dimensional data. A variety of approaches are now an established part of the tool-
kit, and for some models (including sparse linear and generalized linear models), there is a rich mathemat-
ical theory concerning their performance in the high-dimensional setting (Bu¨hlmann and van de Geer,
2011). In a nutshell, the body of empirical and theoretical research has shown that learning predictive
models over large numbers of variables is often feasible and remarkably effective. In applied ML, there
has been a deepening understanding of practical issues, e.g., relating to the transferability of predictions
across contexts (Quin˜onero-Candela et al., 2009), that is very relevant to the clinical setting.
Based on these developments in the data sciences and the increasing availability of GEP data derived
from peripheral blood including AML, we sought to develop near-automated approaches in which ML
tools automatically learn suitable patterns directly from the global transcriptomic data without pre-selec-
tion of genes. To this end, we built the probably largest reference blood GEP dataset comprising 105 in-
dividual studies with, in total, more than 12,000 patient samples. We applied high-dimensional ML
approaches to build genome-wide predictors in an unbiased, entirely data-driven manner and tested
predictive accuracy in held-out data. We emphasize that our goal was not to outperform classical diag-
nostic methods, but to ask whether we could match human annotation in a near-automated and scalable
manner. This aim is common to a number of recent efforts to use ML and AI advances in the diagnostic
setting (see, e.g., Esteva et al., 2017) wherein human-derived labels are used to guide learning. We did
not address the question of subclassification of leukemic disease, where the mutation status of the
leukemic cells is currently the dominant approach (Arber et al., 2016; Heath et al., 2017; Papaemmanuil
et al., 2016; The Cancer Genome Atlas Research Network (TCGA) et al., 2013), but rather focused on
primary diagnosis, which continues to rely mostly on classical approaches (morphology, immunophenotyp-
ing, cytochemistry). We carried out extensive tests designed to address specific concerns relevant to prac-
tical use, including the case of transferring predictive models between entirely disjoint studies (that could
be subject to batch effects or other unwanted variation) and even between transcriptomic platforms. Our
results show that combining ML and blood transcriptomics can yield highly effective and robust classifiers.
This supports the notion that transcriptomic-based ML could be used to assist AML diagnostics, particu-
larly in settings wherein hematological expertise is not sufficiently available and/or costly.
RESULTS
Establishment of a Unique GEP Dataset for Classifier Development
We hypothesized that the determination and comprehensive evaluation of GEP- and ML-based AML
classifiers requires large datasets, should include samples from many sources to mimic the situation in
real-world deployment, and should include several technical platforms to better understand their influence
on classifier performance. To achieve these goals, we wanted to include the largest number of peripheral
blood mononuclear cells (PBMC) or bone marrow samples possible and therefore systematically
searched the National Center for Biotechnology Gene Expression Omnibus (GEO; Edgar, 2002) database
for PBMC and bonemarrow studies (Figure 1A). We identified 153,922 datasets, of which 111,632 contained
human samples. To include only whole sample series and to avoid duplicate samples, we filtered for GEO
series (GSE) and excluded the so-called super series, which resulted in 2,715 studies. We then focused the
analysis on studies with samples analyzed on one of three platforms including the HG-U133A microarray,
the HG-U133 2.0 microarray, and Illumina RNA-seq. Next, duplicated samples and studies working with
pre-filtered cell subsets were excluded. This study search strategy resulted in 105 studies with a total of
12,029 samples (Figure 1) including 2,500 samples assessed by HG-U133A microarray (Dataset 1), 8,348
samples by HG-U133 2.0 microarray (Dataset 2), and 1,181 samples by RNA-seq (Dataset 3). In total, the
dataset contained 4,145 AML samples of diverse disease subtypes and 7,884 other samples derived
from healthy controls (n = 904), patients with acute lymphocytic leukemia (ALL, n = 3,466), chronic myeloid
leukemia (CML, n = 162), chronic lymphocytic leukemia (CLL, n = 770), myelodysplastic syndrome (MDS, n =
267), and other non-leukemic diseases (n = 2,312) (Figures 1B, S1, and S2). Unless otherwise noted, all
samples derived from patients with AML are referred to as cases and non-AML samples as controls. We
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additionally considered a differential diagnosis-like setting, in which case the controls comprised non-AML
leukemias. According to the three platform types, the whole sample cohort was divided into three datasets
referred to as datasets 1, 2, and 3 (Table S1, Figure S1).
Figure 1. Establishing Datasets for the Largest AML Meta-study to Date
(A) Flowchart for the inclusion of studies. The gene expression omnibus (GEO) database was systematically searched for
GEO Series of human PBMC and bone marrow samples processed with microarray platforms (Affymetrix HG-U133A and
HG-U133 2.0) or next-generation RNA sequencing (RNA-seq) data. These data were filtered for inclusion of AML samples,
samples of other leukemia, and healthy samples or other diseases. After manual revision and exclusion of duplicates and
experiments using sorted cell populations (‘‘expert filter’’), the data were combined and normalized independently for
each dataset.
(B) Detailed overview of the three datasets established in this study after filtering as given in (A).
See also Figure S1.
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Effective AML Classification Using High-Dimensional Models
Here, we sought to assess classification of AML versus non-AML. Microarray data were RMA normalized
using the R package affy (Gautier et al., 2004), whereas RNA-seq data were normalized as implemented
in the R package DESeq2 (Love et al., 2014). For further analysis and better comparison between the
different datasets, we trimmed the data to 12,708 genes, which were annotated within all datasets. No
filtering of low expressed genes was performed (Figure 2A). The size of the test set was 20% of the total
sample size, and random sampling of training and test sets was repeated 100 times. As main performance
metrics, we considered (held-out) accuracy, sensitivity, and specificity. Classification was performed using
l1-regularized logistic regression (the lasso; see also later).
First, we included all non-AML samples, consisting of healthy controls and non-leukemic diseases, among
the controls (Figures 2B, 2D, and 2F, light blue lines, Table S2). The goal was to classify unseen samples
as AML or control. To understand how much data is needed in this setting, we plotted learning curves
showing the test set accuracy as a function of training sample size ntrain. For each gene expression platform,
this was done by randomly subsampling ntrain samples and testing on held-out test data with fixed sample
size ntest (as shown). We see that prediction in this setting is already highly effective with a small number of
training samples, although accuracy still increases with increasing ntrain (note that the total number of
samples and hence range of ntrain differs by platform).
In many clinical settings, the control group does not contain healthy controls, but rather related diseases.
To test effectiveness in a differential diagnosis setting, we repeated the experiments but with controls
sampled only from other leukemic diseases, such as ALL, CLL, CML, and MDS (Figures 2C, 2E, S3–S5,
and S13). We observed similar prediction results, which indicated that prediction accuracy is not only
due to large differences between AML and non-leukemic conditions.
In additional experiments we considered performance of nine different classification methods (Figures S3–
S5, Table S4). We could predict AML with good accuracy with all tested classification algorithms on micro-
array platforms (Figures S3 and S4). For RNA-seq data, the lasso, k nearest neighbors, linear support vector
machines, linear discriminant analysis, and random forests were able to predict with high sensitivity
and specificity (Figure S5, for details on used packages see Transparent Methods). Lasso-type methods
have several advantages, including extensive theoretical support and interpretability, so we focused on
these as our main predictive tool. Deep neural networks provided similar prediction performance to
the lasso (Figure 2G) on dataset 2. We preferred the latter in this setting due to interpretability, because
the lasso provides explicit variable selection, facilitating model interpretation.
Evaluation of Positive Predictive Value under Various Prevalence Scenarios
For diagnostic utility, the positive predictive value (PPV; the probability of disease given a positive test
result) is an important quantity. The PPV depends not only on sensitivity and specificity but also on prev-
alence, as it is harder to achieve a high PPV for a condition that is rare in the population of interest.
This has implications for any change to the effective threshold at which a potential case enters the diag-
nostic pipeline. As this threshold is relaxed, the prevalence (in the tested population) decreases, which in
turn reduces the PPV. Thus, although we found high accuracy, sensitivity, and specificity already at mod-
erate ntrain, depending on the use case, this could still imply that large training sample sizes would
be useful to reach acceptable PPVs. For example, the predictive gains in increasing ntrain from the lowest
to the highest values indicated in Figure 2C, which is for the dataset with largest total sample size, corre-
spond to a doubling of PPV from 20% to 40% at an assumed prevalence of 1% (Figure 3). This
illustrates the fact that although after a certain point increasing ntrain tends to increase accuracy only
slowly, the gains, even if small in absolute terms, can be highly relevant with respect to PPV in low-prev-
alence settings.
Assessing the Effect of Cross-Study Variation on Predictive Performance
Microarray data and data generated by high-throughput sequencing are both known to be susceptible to
batch effects (Leek et al., 2010). More generally, diverse study-specific effects and sources of study-to-study
variation can pose problems in the context of predictive tests for clinical applications. Predictors that
perform well within one study may perform worse when applied to data from new studies (Hornung
et al., 2017) with implications for practical generalizability.
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The aforementioned results spanned data frommultiple heterogeneous studies. Provided training and test
data are sampled in the same way, such heterogeneity does not necessarily pose problems for classifica-
tion, as evidenced earlier. However, if the training and test data are from entirely different sites/studies
(rather than randomly sampled from a shared pool), then the impact of batch/study effects may be more
serious. We took advantage of the large number of studies in our dataset to sample training and testing
sets in such a way that they were mutually disjoint with respect to studies. That is, any individual study
from which any sample was included into the training dataset was entirely absent from the test set, and
vice versa, and we use the term cross-study to refer to this strictly disjoint case. Results are shown in Figures
2B, 2D, and 2F (dark blue lines). As expected, performance was worse in the cross-study setting than
under entirely random sampling (light blue lines). However, in the dataset with the largest sample size (da-
taset 2, platform HG-U133 2.0; Figure 2D) we see that the performance in the cross-study case gradually
catches up to the random sampling case with only a small gap at the largest ntrain. The other two datasets
have smaller total sample sizes, so they never reach comparable training sample sizes. Note that we did not
carry out any batch effect removal using tools such as combat (Johnson et al., 2007), SVA (Leek et al., 2012),
or RUV (Jacob et al., 2016), and in that sense our results are conservative. Despite the availability of
these and other tools for batch effect correction, it is difficult to be fully assured of the removal of unwanted
variation in practice. Our intention here was not to remove between-study variation but rather to (conser-
vatively) quantify its effects on accuracy.
Owing to the large number of studies included in our analysis, we were able to carry out an entirely disjoint
cross-study analysis also for the differential diagnosis case. These results are shown in Figures 2C and 2E
(dark blue lines; cross-study sampling for differential diagnosis was not possible using dataset 3 due to
lack of samples, see Figure S1) and are broadly similar, also across different classification algorithms
(Figures S6–S8).
However, even in this strict cross-study sampling scenario, where samples from studies of the training
and testing sets are entirely disjoint, the predictor matrices are still normalized together, meaning that
the prediction rule still depends to some extent on features (not labels) in the test set. To address this issue,
we performed addon RMA normalization (Hornung et al., 2017) as implemented in the R package bapred
(Hornung et al., 2016). We split dataset 1 in training and testing data in a strict cross-study setting as in
Figure 2A, performed RMA normalization on the training data, and then performed addon normalization
of the test data onto the training data, meaning that the normalization of the training data does not in
any sense depend on the testing data (Figure S9A). Accuracy, sensitivity, and specificity of this setting
compare well to the ‘‘classical’’ cross-study setting described earlier (Figures 2 and S6A).
Classification Accuracy and AML Subtypes
Next, we sought to understand whether the accuracy of the classifiers depended on specific AML subtypes.
As only a limited number of samples in our data were already annotated according to the newWorld Health
Organization (WHO) classification, we utilized the French-American-British (FAB) classification of AML. The
FAB classification was available for a total of 616 samples of dataset 1 and 1,269 samples in dataset 2.
We utilized results from train/test splits of datasets 1 and 2 to quantify accuracy for each individual sample
(Figures 4A and 4D). No particular AML subtype dominated classification accuracy in either dataset 1 or 2
(Figures 4C and 4F). Prediction accuracy was also consistent when broken down by non-AML disease
category (Figures 4B and 4E). In dataset 1, 8 MDS samples and 10 samples from patients with Down
syndrome transient myeloproliferative disorder were misclassified. However, both are diseases closely
related to AML and represented by a very limited sample size in dataset 1. For dataset 2, correct classifi-
cation of MDS appeared to depend on the individual sample, potentially reflecting disease heterogeneity.
Figure 2. Prediction of AML in Random and Cross-study Sampling Scenarios
(A) Schema illustrating the approach to predict AML in random and cross-study sampling scenarios.
(B–D) AML classification accuracies based on the lasso model of AML versus all other samples and for both sampling strategies are shown for dataset 1 (B),
dataset 2 (C), and dataset 3 (D).
(E and F) Classification accuracies for the differential diagnosis case (AML versus other leukemic samples, namely, AML, ALL, CML, CLL, and MDS) for both
sampling strategies are shown for dataset 1 (E) and dataset 2 (F). Mean accuracies of the lasso models are shown as a function of the training sample size
ntrain. Results are over 100 random training and test sets, with error bars indicating the standard deviation.
(G) Comparison of the performance of the LASSO models introduced in panels A to F with a neural network approach using either 5 or 10 layers. Error bars
indicate the standard deviation.
See also Figures S3–S8 and S13, and Tables S2 and S4.
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While our main focus is on diagnosis, we asked whether the transcriptomic data could contribute to clas-
sifying AML subtypes. To exemplify this aspect, we focused on AML subtype M3, also named acute pro-
myelocytic leukemia, as this is the only genetically defined subtype of the FAB classification that is also
part of the WHO classification. Using dataset 2, we used a train/test approach, drawing subsets of dataset
2 with approximately the same class balance as in main results (here, one-third AML-M3 cases in every sub-
set) (Figure 4G). M3 was distinguished from non-M3 AMLwith high accuracy, sensitivity, and specificity (Fig-
ure 4H). Although the data here do not allow rigorous testing of transcriptomics combined with genomics
in an integrated fashion for subtype classification, and we would not recommend at this stage the use of a
purely transcriptomic classifier for subtyping, these initial results suggest that it may be useful to further
study the potential value of testing scalable ML- and GEP-based methodology in the area of subclassifi-
cation as well.
Translation of Classifiers across Technical Platforms
Over the long term, clinical pipelines must cope with changes in technological platforms. It is therefore
relevant to understand to what extent predictors can generalize not only between studies but also between
different platforms. In other words, is it possible to take a model learned on data from platform A and
deploy it using unseen data from platform B? To address this question, we constructed AML versus non-
AML training and test sets in a cross-platformmanner, i.e., training on one platform and testing on another
(Figure 5A). That is, a model was learned using independently normalized data from one platform and
then this model, used ‘‘as is,’’ with no further fine-tuning, was used to make predictions using expression
data from a different platform. We see that classification accuracy varies greatly. Classifiers that were
trained on HG-U133 A (dataset 1) work well when tested using data generated with the more advanced mi-
croarray HG-U133 2.0 (dataset 2) (Figures 5B and S10) and models trained on HG-U133 2.0 data can predict
well using RNA-seq data (dataset 3) (Figures 5D and S11). However, models trained naively on HG-U133 A
data cannot predict using RNA-seq data (Figures 5F, S12, and S13, Table S4).
To explore the utility of simple transformations in this context, we then performed a rank transformation to
normality on all datasets (see Transparent Methods). This is among the simplest and best known data trans-
formations, has previously been shown to increase the performance of prognostic gene expression signa-
tures, and can even outperform more complex variance-stabilizing approaches (Zwiener et al., 2014). With
this approach, we reached very good overall performance across all platforms under study (Figures 5C, 5E,
and 5G). This is particularly interesting for the prediction of dataset 3, which fails when the model is trained
on the untransformed dataset 1 (Figures 5F, 5G, S11, and S12) and performs worse (on dataset 3) as ntrain
increases. This is because as ntrain increases, the models learn a pattern that is increasingly fine-tuned to
the data type in the training set. However, because the test set is from a different platform, test perfor-
mance suffers. This is most likely not classical ‘‘overfitting,’’ because as shown in previous figures test error
is well-behaved within dataset 1, but rather an example of a transfer learning/distribution-shift type prob-
lem, which in this case is solved simply by rank transformation. Note that the transformation is simply
applied to each dataset independently and could be easily deployed in any practical use case without
any need for prior input into, e.g., cross-platform designs such as inclusion of control samples.
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Furthermore, we used the rich resource of the present dataset to explore whether prediction across
leukemic diseases would be possible as well. For this, we trained a multilabel-classifier on dataset 2 using
both datasets 1 and 3 as independent validation sets (Figure S14A). We found good prediction accuracy,
sensitivity, and specificity over most tested diseases (Figure S14B); however, a rigorous study over all
leukemic conditions would clearly require the inclusion of more training samples for CLL and CML.
Predictive Signatures and AML Biology
The predictive models derived from the lasso and used earlier are sparse in the sense that they automat-
ically select a small number of genes to drive the prediction. The genes are selected in a unified global anal-
ysis, rather than by differential expression (DE) on a gene-by-gene basis. From a statistical point of view,
global sparsity patterns for prediction and gene-by-gene DE are different criteria. Differentially expressed
genes are those that individually have different levels between the groups, whereas genes selected for
prediction are those that together perform well in a predictive sense. For the lasso, the selected set of
genes also typically includes false-positives with respect to the truly relevant predictors. Furthermore, a
good set of genes for prediction need not be mechanistic (in the sense of constituting causal drivers of
the disease state). We therefore sought to understand the relationship between DE, known mechanisms,
and predictive gene signatures.
Using dataset 2 (the largest dataset) we compared DE and the sparse predictive models (Figure S15). We
performed DE analysis using the whole dataset and compared the results with the set of genes in the lasso
model (‘‘lasso genes’’) based on the same data (Figure 6A). A total of 506 genes was differentially expressed
(‘‘DE genes’’), of which 26 were associated with the disease ontology term or Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway for AML (‘‘AML-related genes’’). Of the 141 lasso genes, 7 genes were
leukemia related and 46 were DE genes, meaning that many of the lasso genes were not differentially ex-
pressed, as clearly seen when overlaying the lasso gene selection on a volcano plot (Figure 6A). This under-
lines the fact that DE and predictive value in a signature sense are different criteria.
Next, we extended this analysis to focus on DE and lasso genes whose selection was robust to data sub-
sampling. This was done by subsampling half the dataset randomly 100 times and in each such subsample
carrying out the full DE and lasso analyses. For the lasso this type of approach has been studied under
the name stability selection (Meinshausen and Bu¨hlmann, 2010). DE and lasso genes were then scored
according to the frequency with which they appeared among the 100 rounds of selection (Figure 6B).
Thus, an inclusion score of 100% for a DE gene means that the gene is selected as differentially expressed
in all 100 iterations, and similarly for the lasso genes. In total, 669 genes passed the DE cutoffs in at least
50% of the iterations, whereas 80 genes were called in at least 50% of the iterations by the lasso model (Fig-
ure 6B). Of these genes, 35 were called according to both criteria. The above-mentioned results show that
even among the genes that are included in the lasso models with high frequency (i.e., those genes that are
robustly selected for prediction), many are not differentially expressed.
Next, we excluded the 155 known AML genes that are associated with the disease ontology term or
KEGG pathway for AML from the prediction, which did not affect disease prediction at all (Figure 6C), high-
lighting the strong robustness of the classifier. To better understand the potential biological relevance for
AML of the 35 genes that were robustly called under both DE and lasso criteria (Figure 6B), we visualized the
top-ranked genes over all 8,348 samples within the dataset by hierarchical clustering of z-transformed
expression values (Figure 6D). We identified one distinct cluster of genes with the majority of genes being
elevated in AML compared with other leukemias and non-leukemic samples (cluster 1, n = 29). Although we
identified several well-known AML-related genes (gene name in red color) such as the KIT Proto-Oncogene
Receptor Tyrosine Kinase (KIT) (Gao et al., 2015; Heo et al., 2017; Ikeda et al., 1991), RUNX2 (Kuo et al.,
2009), and FLT3 (Bullinger et al., 2008; Carow et al., 1996) in this cluster, many genes have not yet been
Figure 4. Accuracy of AML Classification in Different Leukemia Types and AML Subclasses
(A) Schema for determining accuracy for leukemia types and AML subclasses in dataset 1.
(B–D) Normalized dataset 1 was randomly split into training and test sets 100 times (same permutations as in Figure 2B), and prediction accuracy is reported
for each individual sample. The bars in the figure correspond to individual samples broken down by leukemia type (B) and AML subtype (C). (D) Schema for
determining accuracy for leukemia types and AML subclasses in dataset 2.
(E–H) Normalized dataset 2 was randomly split into training and test sets 100 times (D) and prediction accuracy is reported for each individual sample, listed
by leukemia type (E) and AML subtype (F). Workflow for M3 subtype prediction using dataset 2 (G) Boxplots of prediction accuracy, sensitivity, and specificity
over 100 train/test splits (H). Error bars depict the standard deviation.
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linked to AML biology, and, although not the focus of the present article, further study of these genes may
be interesting from a mechanistic point of view. Within the other cluster (cluster 2, n = 6 genes), genes had
reduced expression values in AML compared with other leukemias and two of these genes have been
linked to other types of leukemias (gene names in orange color).
DISCUSSION
Despite the pioneering studies by Golub and others (Debernardi et al., 2003; Kohlmann et al., 2003; Ross
et al., 2004; Schoch et al., 2002; Virtaneva et al., 2001) suggesting high potential value of GEP for primary
AML diagnosis and differential diagnosis, current recommendations for diagnosing this disease currently
center on classical approaches including assessment of morphology, immunophenotyping, cytochemistry,
and cytogenetics (Do¨hner et al., 2017). Analyzing more than 12,000 samples from more than 100 individual
studies, we provide evidence that combining large transcriptomic data withML allows for the development
of robust disease classifiers. Such classifiers could, in the future, potentially assist in primary diagnosis of
this deadly disease particularly in settings where hematological expertise is not sufficiently available
and/or costly. Considering the increased utilization of whole-genome and whole-transcriptome
sequencing in the management of patients with cancer, we propose that application of GEP- and ML-
based classifiers for diagnosis needs to be re-evaluated. This is in line with previous suggestions by the In-
ternational Microarray Innovations in Leukemia Study Group (Haferlach et al., 2010). Furthermore, we sug-
gest that similar analyses may be useful for other diseases when analyzing whole blood or PBMC-derived
gene expression profiles, or for multiple conditions in parallel (see later).
We sought to understand and address some of the bottlenecks in the way of clinical deployment of
transcriptomic-based ML tools for diagnosis. To this end, we considered a range of practical scenarios,
including cross-study issues and prediction across different technological platforms. We found that accu-
rate prediction is possible across a range of scenarios and, in many cases, with relatively few training sam-
ples. However, we also showed that depending on the use case and the associated prevalence, large
training sets may be required to reach accuracies high enough to yield acceptable PPVs.
Our results show that with existing technologies it is potentially possible to achieve good performance in
a near-automated fashion. An ML-plus-genomics approach can be run at very low marginal cost: the RNA
assays can already be done at <$100 (and this continues to fall), and in the long-term these costs will drop
still further. To our knowledge, this is already in a cost range that is lower than the combined use of
morphology, immunophenotyping, and cytochemistry for primary AML diagnosis. Furthermore, the sparse
models we considered, once trained, require only a small subset of the genome, hence custom sequencing
pipelines could be used. Marginal cost is important precisely because it opens up the possibility of a truly
scalable detection/diagnosis strategy. One example of a recently developed, very-low-cost whole-tran-
scriptomics protocol is BRB-seq which allows generating genome-wide transcriptomic data at a similar
cost as profiling four genes using RT-qPCR (Alpern et al., 2019), which could be a candidate for future clin-
ical development. Furthermore, recent developments in nanopore sequencing (Byrne et al., 2017) suggest
that in the future, delivery of transcriptomic assays could be greatly simplified, and this, combined with
cloud- or local-device-based ML prediction, would represent a paradigm shift in terms of scalability and
accessibility. Such transcriptome-based ML might therefore also be utilized at an earlier time point in
the disease course, when patients present with non-specific symptoms to their primary care physician.
Here, ML-based diagnostics might assist a faster transfer of the patient to specialized hematology centers
for complete diagnostics and therapeutic management.
The next steps toward better understanding ML-based diagnosis for AML would include prospective
studies specifically aimed at assessing diagnostic utility. Before any development in the future pivotal clin-
ical trials for approval with the respective regulatory bodies would be required. Naturally, any such devel-
opment would require additional, independent studies with the development of deployment-ready
Figure 5. Translating Predictive Signatures across Technological Platforms
(A) Schema of signature translation across platforms. Datasets were normalized individually and trimmed to 12,708 common genes. The classifiers were
trained on subsamples of different sizes on one platform and tested on all samples of another platform.
(B–G) Classification accuracies are shown as a function of training sample size (ntrain) without rank transformation (B, D, and F) and with rank transformation (C,
E, and G). For the latter case, the training and test datasets (from different platforms) were separately rank transformed (see text for details). Error bars depict
the standard deviation.
See also Figures S10–S13.
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pipelines, which by itself is a nontrivial undertaking (as discussed in Keane and Topol, 2018). However,
initial prospective studies have already been started, such as the 5000 genomes project (https://www.
mll.com/en/science/5000-genome-project.html), which also performs RNA-seq to develop such a classifier
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Figure 6. Predictive Signatures and AML Biology
(A) Volcano plot of global differentially expressed (DE) genes and genes of the lasso model (‘‘lasso genes’’) in dataset 2,
and Venn diagram indicating the overlap of both gene sets and the genes included in the KEGG pathway or the disease
ontology term ‘‘AML.’’
(B) Inclusion plot of DE genes and lasso genes in 100 random permutations of dataset 2. The plot is sorted according to
DE gene rank, and a Venn diagram shows the overlap between genes with a minimum of 50% inclusion.
(C) Boxplot of accuracy, sensitivity, and specificity of the predictive model trained and tested on random subsets of
dataset 2 with inclusion of all genes of the dataset and without 155 genes known to be relevant for AML biology. Error bars
depict the standard deviation.
(D) Heatmap and hierarchical clustering of z-scaled expression values of 35 genes with >50% inclusion both in lasso and
DE genes, as shown in (B). Genes with known associations with AML are marked red; genes associated with other types of
leukemia are labeled in orange.
See also Figure S15.
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for the clinics. It is also important to emphasize that just as regulatory standards have evolved for classical
diagnostics, so too will new regulatory frameworks be needed for ML-assisted diagnostics in the future
(Keane and Topol, 2018).
An additional point concerns explicit and implicit thresholds at which a suspected case is entered into
the pipeline in the first place. A lower threshold for entry could lower false-negatives and reduce the risk
of delayed treatment (which has been associated with worse outcomes, notably in younger patients;
Sekeres et al., 2008). Using current diagnostic systems any such change would dramatically increase the
overall costs; in contrast, more efficient solutions would allow thresholds to be optimized for patient benefit
while keeping the overall costs controlled. Naturally any modification to the overall diagnostic strategy
would need a full health economic and decision analysis (accounting in particular for a necessarily higher
false-positive rate) and case-by-case assessment. For some diseases it may be the case that earlier entry
into a diagnostic pipeline would overall not be beneficial, a point that is widely appreciated in the context
of population-level screening (see, e.g., Jacobs et al., 2016). Nevertheless, the point is that scalable diag-
nostic strategies increase the scope for optimization of decision making for patient benefit.
We saw also encouraging results across other conditions. Although the data used in the present study do
not allow rigorous study of diagnosis across multiple conditions, we conjecture that diagnosis of multiple
conditions from blood transcriptomes may be possible, opening up the possibility of training multi-class
classifiers on blood transcriptomic data. Note that this would allow diagnosis of several conditions at
essentially the same marginal cost per additional sample, bolstering the economic case outlined earlier.
Rigorous study would require new pan-disease study designs, but we think that such approaches could
lead to large efficiency gains in the future.
All our models were learned in an unbiased manner, directly from the full transcriptome data with no prior
biological knowledge or any pre-selection of genes. We showed that genes relevant for prediction were
often not differentially expressed and that prediction was robust to removal of known AML-related genes.
These observations illustrate two points of relevance to clinical applications. First, for prediction it can be
more fruitful to consider signatures derived in data-driven, genome-wide fashion than to think in terms of
single genes or DE. Second, high-dimensional analyses, although complex relative to more classical
methods, can be highly predictive as well as robust to the presence or absence of specific genes. Taken
together, our results underline the immense value of making GEP data publicly available, allowing
for new and large-scale multi-study analyses. Furthermore, we support the notion that the application of
ML approaches based on sequencing data to identify gene signatures for certain diseases such as AML
will become part of recommendations for diagnosis andmanagement of AML. We envision that combining
whole-genome and whole-transcriptome analysis based on ML algorithms will ultimately allow early
detection, diagnosis, differential diagnosis, subclassification, and outcome prediction in an integrated
fashion.
Limitations of the Study
It is important to note that the data used here were pooled from multiple studies with different designs
and goals. Further work, including suitably designed prospective studies, would be needed to better
understand the diagnostic utility of an ML-plus-transcriptomics approach. Site- and study-specific effects
may be relevant for clinical applications. This is because a classifier once learned might be deployed in a
range of new settings (sites, regions) that could lead in a number of ways to unwanted variation. If training
and test sets are very different, this can impact performance. In clinical applications of predictive models
it will be important to continually track performance even after deployment and the possibility of distribu-
tional shifts that require more complex analyses cannot be ruled out.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY
Processed data can be accessed via the SuperSeries GSE122517 or via the individual SubSeries GSE122505
(dataset 1), GSE122511 (dataset 2), and GSE122515 (dataset 3). The code for preprocessing and for predic-
tions can be found at GitHub (https://github.com/schultzelab/aml_classifer). In addition, all data and
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package versions are stored in a docker container on Docker Hub (https://hub.docker.com/r/schultzelab/
aml_classifier, Table S3).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.100780.
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Supplemental Figure Legends 
 
Figure S1: Sample overview, related to Figure 2 
(A) Overview of the sample and study composition of all three datasets. The GSE number and the number 
of samples per disease are depicted for each study.  
 
Figure S2: Comparison of bone marrow and PBMC samples, related to Figure 1 
(A) Workflow: Dataset 2 was used to sample bone marrow and PBMC samples of AML patients and controls 
in equal numbers. (B) The resulting dataset of 332 samples was scaled and gene expression values of the 
top 25% variable genes were clustered and shown in a dendrogram.   
 
Figure S3: Prediction of AML in random sampling scenarios (dataset 1), related to Figure 2 
(A) Workflow: Dataset 1 (Affymetrix HG-U133 A) was RMA normalized and subjected to 100 times random 
sampling of training and test data, with training data samples from ntrain = 100 to ntrain = 2000 samples and 
test data of ntest = 500 samples. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on the whole dataset 1. (C) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on leukemia samples of dataset 1 (AML, ALL, CML, CLL, MDS and down syndrome transient 
myeloproliferative disorder). Errorbars depict the standard deviation. 
 
Figure S4: Prediction of AML in random sampling scenarios (dataset 2), related to Figure 2 
(A) Workflow: Dataset 2 (Affymetrix HG-U133 2.0) was RMA normalized and subjected to 100 times random 
sampling of training and test data, with training data samples from ntrain = 100 to ntrain = 6679 samples and 
test data of ntest = 1669 samples. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on the whole dataset 2. (C) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on leukemia samples of dataset 1 (AML, ALL, CML, CLL, MDS). Errorbars depict the standard 
deviation. 
 
Figure S5: Prediction of AML in random sampling scenarios (dataset 3), related to Figure 2 
(A) Workflow: Dataset 3 (RNA-seq) was normalized using DESeq2 and subjected to 100 times random 
sampling of training and test data, with training data samples from ntrain = 100 to ntrain = 945 samples and 
test data of ntest = 236 samples. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on the whole dataset 3. Prediction of leukemia samples only was not possible due to small 
sample sizes (see Figure S1). Errorbars depict the standard deviation. 
 
Figure S6: Prediction of AML in cross-study sampling scenarios (dataset 1), related to Figure 2 
(A) Workflow: Dataset 1 (Affymetrix HG-U133 A) was RMA normalized and subjected to 100 times cross-
study sampling of training and test data. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on cross-study sampling on the whole dataset 1, with training data samples from ntrain = 100 to 
ntrain = 1865 (mean) samples and test data of ntest = 500 samples. (C) Accuracy, sensitivity and specificity 
for nine different prediction algorithms on cross-study sampling of leukemia samples of dataset 1 (AML, 
ALL, CML, CLL, MDS and down syndrome transient myeloproliferative disorder), with training data samples 
from ntrain = 100 to ntrain = 1480 (mean) samples and test data of ntest = 436 samples. Errorbars depict the 
standard deviation. 
Figure S7: Effective prediction of AML in cross-study sampling scenarios (dataset 2), related to 
Figure 2 
(A) Workflow: Dataset 2 (Affymetrix HG-U133 2.0) was RMA normalized and subjected to 100 times cross-
study sampling of training and test data. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on cross-study sampling on the whole dataset 1, with training data samples from ntrain = 100 to 
ntrain = 5926 (mean) samples and test data of ntest = 1669 samples. (C) Accuracy, sensitivity and specificity 
for nine different prediction algorithms on cross-study sampling of leukemia samples of dataset 1 (AML, 
ALL, CML, CLL and MDS), with training data samples from ntrain = 100 to ntrain = 1750 (mean) samples and 
test data of ntest = 1210 samples. Errorbars depict the standard deviation. 
 
Figure S8: Effective prediction of AML in cross-study sampling scenarios (dataset 3), related to 
Figure 2 
(A) Workflow: Dataset 3 (RNA-seq) was normalized using DESeq2 and subjected to 100 times cross-study 
sampling of training and test data. (B) Accuracy, sensitivity and specificity for nine different prediction 
algorithms on cross-study sampling on the whole dataset 3, with training data samples from ntrain = 100 to 
ntrain = 889 (mean) samples and test data of ntest = 236 samples. Prediction of leukemia samples only was 
not possible due to small sample sizes (see Figure S1). Errorbars depict the standard deviation. 
 
Figure S9: Addon RMA normalization, related to Figure 2 
(A) Schema for addon RMA normalization on dataset 1. The 2500 samples were subjected to 50 times 
cross-study sampling, which corresponds to the first 50 permutations in Figure 5SA. Different to the 
aforementioned approach, the data was not normalized beforehand, but after splitting the samples into 
training and test data. Training data was RMA-normalized and testing data was normalized “onto” the 
training data using addon normalization. (B) Accuracy, sensitivity and specificity of addon normalization as 
shown in (A) (light blue), compared to performance of the “standard” cross-study sampling approach as 
described in Figure 5SA.  
 
Figure S10: Translating predictive signature across technological platforms (setting 1), related to 
Figure 4 
(A) Workflow: Datasets were normalized individually and trimmed to 12,708 common genes. The predictors 
were trained on subsamples of different sizes on dataset 1 and tested on all samples of dataset 2. (B) 
Accuracy, sensitivity and specificity of lasso prediction trained on dataset 1 with training sample size from 
ntrain = 100 to ntrain = 2500 and tested on the full dataset 2 (ntest = 8348). (C) Accuracy, sensitivity and 
specificity of lasso prediction trained on rank transformed dataset 1 with training sample size from ntrain = 
100 to ntrain = 2500 and tested on the full dataset 2 (ntest = 8348, rank transformed). Errorbars depict the 
standard deviation. 
 
Figure S11: Translating predictive signature across technological platforms (setting 2), related to 
Figure 4 
(A) Workflow: Datasets were normalized individually and trimmed to 12708 common genes. The predictors 
were trained on subsamples of different sizes on dataset 2 and tested on all samples of dataset 3. (B) 
Accuracy, sensitivity and specificity of lasso prediction trained on dataset 2 with training sample size from 
ntrain = 100 to ntrain = 8348 and tested on the full dataset 3 (ntest = 1181). (C) Accuracy, sensitivity and 
specificity of lasso prediction trained on rank transformed dataset 2 with training sample size from ntrain = 
100 to ntrain = 8348 and tested on the full dataset 3 (ntest = 1181, rank transformed). Errorbars depict the 
standard deviation. 
Figure S12: Translating predictive signature across technological platforms (setting 3), related to 
Figure 4 
(A) Workflow: Datasets were normalized individually and trimmed to 12708 common genes. The predictors 
were trained on subsamples of different sizes on dataset 1 and tested on all samples of dataset 3. (B) 
Accuracy, sensitivity and specificity of lasso prediction trained on dataset 1 with training sample size from 
ntrain = 100 to ntrain = 2500 and tested on the full dataset 3 (ntest = 1181). (C) Accuracy, sensitivity and 
specificity of lasso prediction trained on rank transformed dataset 1 with training sample size from ntrain = 
100 to ntrain = 2500 and tested on the full dataset 3 (ntest = 1181, rank transformed). Errorbars depict the 
standard deviation. 
 
Figure S13: F1 scores of AML prediction in random sampling, cross-study and cross-platform 
scenarios, related to Figures 2 and 5 
 
F1 scores of prediction results in random and cross-study sampling scenarios in dataset 1, all samples 
(A), dataset 1, leukemia samples only (B), dataset 2, all samples (C), dataset 2, leukemia samples only 
(D), and dataset 3, all samples (E). F1 scores for cross-platform prediction results for the settings 
depicted in Figure 5. (F-K).  
 
Figure S14: Pan-leukemia classification across platforms, related to Figure 4 
(A) Workflow: Datasets were normalized individually and trimmed to 12708 common genes and samples 
were filtered to include only AML, ALL, CML, CLL and healthy samples. A multilabel logistic regression 
model was fit on dataset 2 and then tested on the independently normalized datasets 1 and 3. (B,C) 
Confusion matrices comparing predicted labels to true labels for all tested leukemia types for testing on 
dataset 1 and 3, respectively. (D,E) Balanced accuracy, sensitivity and specificity of the multiclass 
prediction on dataset 1 and 3.   
 
Figure S15: Workflow: Comparing differentially expressed and predictive genes, related to Figure 5 
(A) Workflow to Figure 5: Dataset 2 was used to compare DE and the sparse predictive models. First, a 
global analysis of DE genes and lasso genes was performed and visualized in a heatmap. Second, dataset 
2 was permuted and 35 genes that appeared at least 50 out of 100 times as “DE gene” or “lasso gene” 
were visualized in a heatmap. Third, predictive signatures were trained on all 12708 genes, with and without 
155 known AML genes (genes included in DO and KEGG terms). Results were visualized in a boxplot.  
(B) Comparison of “lasso genes” of the prediction AML vs. all samples and AML vs. other leukemia samples 
of dataset 2 (same prediction setting as in Figures 2D, E).  
 
  
Transparent Methods 
Study search strategy 
All data sets published in the National Center for Biotechnology Information Gene Expression Omnibus 
(GEO, (Edgar, 2002)) on 20 September 2017 were reviewed for inclusion in the present study. Basic 
criteria for inclusion were the cell type under study (human peripheral blood mononuclear cells (PMBCs) 
and/or bone marrow samples) as well as the species (Homo sapiens). Both tissues are considered 
equivalent in the diagnosis of AML. We compared bone marrow and PBMC samples of dataset 2 and did 
not identify overall differences in gene expression (Figure S2) and therefore did not differentiate between 
bone marrow and PBMC samples throughout the study. Furthermore, we excluded GEO SuperSeries to 
avoid duplicated samples (Table S1). We filtered the datasets for data generated with Affymetrix HG-
U133 A microarrays, Affymetrix HG-U133 2.0 microarrays and high-throughput RNA sequencing (RNA-
seq) and excluded studies with very small sample sizes (< 50 samples for microarray and < 10 samples 
for RNA-seq data). We then applied a disease-specific search, in which we filtered for acute myeloid 
leukemia, other leukemia and healthy or non-leukemia-related samples. 
The results of this search strategy were then internally reviewed and data were excluded based on the 
following criteria: (i) exclusion of duplicated samples, (ii) exclusion of studies that sorted single cell types 
(e.g. T cells or B cells) prior to gene expression profiling, (iii) exclusion of studies with inaccessible data. 
Other than that, no studies were excluded from our analysis (see also Table S1). In addition, we included 
one unpublished dataset (in dataset 1). The above steps gave rise to the data referred to above as dataset 
1 (Affymetrix HG-U133 A microarrays), dataset 2 (Affymetrix HG-U133 2.0 microarrays) and dataset 3 
(RNA-seq). The RNA-seq data contained was not filtered for any particular protocol and contained paired 
and well as single-end data of different sequencing depth. AML subtype annotations were taken from the 
respective metadata-files on GEO. Subgroups of FAB-classifications were combined to represent the major 
FAB class (e.g. AML M3 and AML M3v were combined to AML M3).  
Pre-processing 
All raw data files were downloaded from GEO. For normalization, we considered all platforms 
independently, meaning that normalization was performed separately for the samples in dataset 1, 2 and 
3, respectively. Microarray data (datasets 1 and 2) were normalized using the robust multichip average 
(RMA) expression measures (Irizarry et al., 2003), as implemented in the R package affy (Gautier et al., 
2004). RNA-seq data (dataset 3) was preprocessed using kallisto (Bray et al., 2016) and normalized with 
the R package DESeq2 using standard parameters (Love et al., 2014). In order to keep the datasets 
comparable, we filtered the data for genes annotated in all three datasets, which resulted in 12,708 genes. 
No filtering of low-expressed genes was performed. All scripts used in this study for pre-processing are 
provided as a docker container on Docker Hub (https://hub.docker.com/r/schultzelab/aml_classifier). 
Prediction  
Prior to classification, data sets were split into non-overlapping training and test data. For the comparisons 
of AML vs. all samples, all non-AML samples were used as controls, which would in clinical terms, reflect 
finding a diagnosis. For the prediction of AML vs. other leukemia, all non-AML leukemias, namely chronic 
myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), 
Myelodysplastic syndrome (MDS) and down syndrome transient myeloproliferative disorder were used as 
non-AML labels, which would be the equivalent of finding a differential diagnosis between different 
leukemias. All main classification tasks were performed in the programming language R (R Core Team, 
2016). All main results were obtained using l1-penalized logistic regression using the package glmnet 
(Friedman et al., 2010). Non-zero coefficients were extracted for feature ranking (Figure 4). The 
regularization parameter was set using 10-fold cross-validation (using training set data only). To assess 
predictive performance, accuracy, sensitivity, specificity and F1 score were calculated as well as positive 
predictive value (PPV) under several prevalence scenarios. For assessing the performance of support 
vector machines (SVMs), we used the R package e1071 for SVMs (linear, radial, polynomial and sigmoid 
kernels) (Meyer et al., 2015). The R package randomForest was used for random forest classification (Shi 
et al., 2004). K nearest neighbors classification was done using the knn function implemented in the class 
package in R (Venables and Ripley, 2002). Linear discriminant analysis was performed with the lda function 
implemented in the R package MASS (Venables and Ripley, 2002). For RNA-seq data, features with zero 
variance were excluded for LDA. Prediction analysis of microarrays was done with the pamr package 
(Hastie et al., 2014). Neural networks were built using Keras (Chollet et al., 2017) with a Tensorflow 
backend (10 layers, ~7×106 parameters). Unless otherwise noted, default settings were used for tuning 
parameters as implemented in the respective packages.  
Rank transformation to normality 
As an example of a simple data transformation that would facilitate translation between gene expression 
platforms, we performed a rank transformation to normality. For this, gene expression values were 
transformed from microarray intensities (dataset 1 & 2) or RNAseq counts to their respective ranks. This 
was done gene-wise, meaning all gene expression values per gene were given a rank based on ordering 
them from lowest to highest value. The rankings were then turned into quantiles and transformed via the 
inverse cumulative distribution function of the Normal distribution. This leads to all genes following the exact 
same distribution (that is, a standard Normal with a mean of 0 and a standard deviation of 1) across all 
samples (Zwiener et al., 2014).  
Differential expression analysis 
For differential expression analysis of dataset 2 the R package limma was used (Ritchie et al., 2015). A 
linear model was fit on the data with inclusion of the study as a factor. Differentially expressed genes were 
called using an FDR-corrected p-value < 0.05 and a minimum fold change of +/- 2. For the permutation-
based approach, 4174 samples were randomly drawn 100 times from the dataset. In each subset, DE 
genes were called as before, but without correcting for any batch in the model. The number of times each 
gene was called was summed up over all 100 permutations. Genes were ranked according to their overall 
DE count.  
In addition to that a l1-penalized logistic regression was performed using the package glmnet (Friedman et 
al., 2010) on the whole dataset and on each of the permutations. Genes were called to be of predictive 
importance if features had non-zero coefficients. The number of times each feature was of predictive 
importance was summed up, which resulted in a feature ranking of all “lasso genes”.  
Hierarchical Clustering  
35 genes which had a stability of > 50% over 100 permutations for lasso and DE genes were visualized 
using the R package pheatmap (Kolde, 2015) (Figure 6B). The data was z-scaled and columns clustered 
according to Euclidean distance. Rows were ordered according to diseases. Two gene clusters were 
visualized. 
Exclusion of gene sets from prediction 
In order to evaluate the robustness of our classification results (Figure 6C), we excluded 155 genes present 
in either the KEGG or the disease ontology term “Acute Myeloid Leukemia” and compared this to the results 
achieved when all 12078 genes of the dataset are included (random sampling, dataset 2).  
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